Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

504277 CB2 Inverse Agonist, SR 144528 - CAS 192703-06-3 - Calbiochem

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 5-​(4-​chloro-​3-​methylphenyl)-​1-​[(4-​methylphenyl)methyl]-​N-​[(1S,​2S,​4R)-​1,​3,​3-​trimethylbicyclo[2.2.1]hept-​2-​yl]-​1H-​pyrazole-3

Primary Target: CB₂ Receptor
504277
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
192703-06-3C₂₉H₃₄ClN₃O
Description
Overview

This product has been discontinued.



A selective inverse agonist for peripheral cannabinoid (CB2) receptors (Ki = 0.6 nM and 400 nM for CB2 and CB1 receptors, respectively). Has been used in studies related to control of pain initiation, suppression of inflammation, and immune activation.
Catalogue Number504277
Brand Family Calbiochem®
Synonyms5-​(4-​chloro-​3-​methylphenyl)-​1-​[(4-​methylphenyl)methyl]-​N-​[(1S,​2S,​4R)-​1,​3,​3-​trimethylbicyclo[2.2.1]hept-​2-​yl]-​1H-​pyrazole-3
References
ReferencesBarth, F., et al. 1999. Curr. Med. Chem. 6, 745.
Iwamura, H., et al. 2001. J. Pharmacol. Exp. Ther. 296, 420.
Wright, K., et al. 2008. Br. J. Pharmacol. 153, 263.
Di Marzo, V. 2008. Nat. Rev. Drug Discov. 7, 438.
Rinaldi-Carmona, M., et al. 1998. J. Pharmacol. Exp. Ther. 284, 644.
Portier, M., et al. 1999. J. Pharmacol. Exp. Ther. 288, 582.
Product Information
CAS number192703-06-3
FormOff-white solid
Hill FormulaC₂₉H₃₄ClN₃O
Chemical formulaC₂₉H₃₄ClN₃O
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetCB₂ Receptor
Primary Target K<sub>i</sub>0.6 nM and 400 nM for CB₂ and CB₁ receptors, respectively.
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
504277 0

Documentation

CB2 Inverse Agonist, SR 144528 - CAS 192703-06-3 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Barth, F., et al. 1999. Curr. Med. Chem. 6, 745.
Iwamura, H., et al. 2001. J. Pharmacol. Exp. Ther. 296, 420.
Wright, K., et al. 2008. Br. J. Pharmacol. 153, 263.
Di Marzo, V. 2008. Nat. Rev. Drug Discov. 7, 438.
Rinaldi-Carmona, M., et al. 1998. J. Pharmacol. Exp. Ther. 284, 644.
Portier, M., et al. 1999. J. Pharmacol. Exp. Ther. 288, 582.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision28-June-2013 JSW
Synonyms5-​(4-​chloro-​3-​methylphenyl)-​1-​[(4-​methylphenyl)methyl]-​N-​[(1S,​2S,​4R)-​1,​3,​3-​trimethylbicyclo[2.2.1]hept-​2-​yl]-​1H-​pyrazole-3
DescriptionA selective inverse agonist for peripheral cannabinoid (CB2) receptors (Ki = 0.6 nM and 400 nM for CB2 and CB1 receptors, respectively). Has been used in studies related to control of pain initiation, suppression of inflammation, and immune activation.
FormOff-white solid
CAS number192703-06-3
Chemical formulaC₂₉H₃₄ClN₃O
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (20 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesBarth, F., et al. 1999. Curr. Med. Chem. 6, 745.
Iwamura, H., et al. 2001. J. Pharmacol. Exp. Ther. 296, 420.
Wright, K., et al. 2008. Br. J. Pharmacol. 153, 263.
Di Marzo, V. 2008. Nat. Rev. Drug Discov. 7, 438.
Rinaldi-Carmona, M., et al. 1998. J. Pharmacol. Exp. Ther. 284, 644.
Portier, M., et al. 1999. J. Pharmacol. Exp. Ther. 288, 582.